报价延迟最少15分钟:2026/08/31 10:23 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.385 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.05/-2.95
|
|
企业价值
18.44M
|
| 资产负债 |
|
每股账面净值
1.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. |
